ライフサイエンスコーパス: graft failure

1 8(+) T cells associated with reduced risk of graft failure.

2 ents are at increased risks of rejection and graft failure.

3 n hypertension might indicate higher risk of graft failure.

4 ID-19 did not increase risk for mortality or graft failure.

5 The primary outcome was 10-year graft failure.

6 to identify the risk factors associated with graft failure.

7 d >30 years had a RR of 1.94 (1.59-2.35) for graft failure.

8 Two eyes (2.0%) experienced primary graft failure.

9 en post-donation systolic blood pressure and graft failure.

10 ificant decrease in kidney function prior to graft failure.

11 une, to gain better insight in the causes of graft failure.

12 significantly associated with death-censored graft failure.

13 stitial fibrosis scores were associated with graft failure.

14 echanisms, would suggest strategies to limit graft failure.

15 rter signals in urine can be detected before graft failure.

16 The outcome monitored was 3-month graft failure.

17 ciated with increased rates of rejection and graft failure.

18 Cox regression was used to model the risk of graft failure.

19 tage-specific milestones, as well as data on graft failure.

20 R) has emerged as an important cause of lung graft failure.

21 0.01) was associated with decreased risk of graft failure.

22 ction were associated with increased risk of graft failure.

23 tivated in the animal which experienced late graft failure.

24 auses microencapsulated islet-cell death and graft failure.

25 ntly associated with total or death-censored graft failure.

26 of congenital glaucoma were risk factors for graft failure.

27 n hypertension might indicate higher risk of graft failure.

28 remains the leading cause of nonimmunologic graft failure.

29 munologic rejection, herpetic recurrence and graft failure.

30 Forty-two patients (3.7%) had 2-week graft failure.

31 n pretransplant skin cancer, PTM, death, and graft failure.

32 , 149 (21%) RTRs died and 82 (12%) developed graft failure.

33 n (NODAT), delayed graft function (DGF), and graft failure.

34 atients were at greater risk of rejection or graft failure.

35 Two children experienced primary graft failure.

36 imal hyperplasia, which is the main cause of graft failure.

37 limited by the lack of robust predictors of graft failure.

38 4; P = 0.024) were risk factors for pancreas graft failure.

39 ion between recipient sex and death-censored graft failure.

40 mune responses remain a significant cause of graft failure.

41 tcomes including a 100% risk of dying before graft failure.

42 al function over 24 months of follow-up, and graft failure.

43 or early adulthood have the highest risk of graft failure.

44 rred, and 6% of the eyes developed secondary graft failure.

45 membrane was observed, eventually leading to graft failure.

46 ficant retrocorneal membranes at the time of graft failure.

47 atified by time post-transplant or time post-graft failure.

48 een postdonation systolic blood pressure and graft failure.

49 gnificant decrease in kidney function before graft failure.

50 ll loss (%ECL), rebubbling rate, and re-DMEK graft failure.

51 practices for the prevention of VGD and vein graft failure.

52 antibodies were not clearly associated with graft failure.

53 glaucoma were significantly associated with graft failure.

54 tivity to these antigens was associated with graft failure.

55 e, to gain better insight into the causes of graft failure.

56 lar hyalinosis also predicted death-censored graft failure.

57 There were no cases of graft failure.

58 opsy-proven acute rejections with subsequent graft failures.

59 elial failure accounted for more than 60% of graft failures.

60 elial failure accounted for more than 60% of graft failures.

61 e RA versus 71% for the SV (hazard ratio for graft failure, 0.40 [95% CI, 0.15-1.00]), and 10-year pa

62 A versus 80% for free RITA (hazard ratio for graft failure, 0.45 [95% CI, 0.23-0.88]).

63 trinsic acute allograft failure, 27 prerenal graft failures, 118 patients with stable graft function,

64 ervation Time Study that had not experienced graft failure 3 years after DSAEK were included.

65 ervation Time Study that had not experienced graft failure 3 years after DSAEK, performed primarily f

66 nin amounts in the highest 50% had a risk of graft failure 3.59 times as high (95% confidence interva

67 controls (54.8 ng/mL, P = 0.70) and prerenal graft failure (53.8 ng/mL, P = 0.62).

68 uppression: malignancy (16.4%), nonrejection graft failure (9.8%), and infection (10.5%) (P < 0.001).

69 models for the primary outcomes of all-cause graft failure (ACGF) and 12-month estimated glomerular f

70 Although there was no difference in risk of graft failure across all age groups, both younger and ol

71 eveloped hypertension had no higher risk for graft failure (adjusted hazard ratio [aHR] 1.03, 95% con

72 ssociated with a 2.6-fold increase in kidney graft failure (adjusted hazard ratio [aHR] 2.63, P < 0.0

73 as no significant difference in the risks of graft failure (adjusted hazard ratio [aHR] = 0.861.001.1

74 ents were at significantly increased risk of graft failure (adjusted hazard ratio [aHR] = 1.6; P = .0

75 ficant association between CIT and all-cause graft failure (adjusted hazard ratio [aHR]: 1.01, 95% CI

76 .02] ml/min per 1.73 m(2)) and lower risk of graft failure (adjusted hazard ratio, 0.50 [95% CI, 0.27

77 eas grafts were lost due to patient death or graft failure after >25 years.

78 de novo DSA formation, graft rejection, and graft failure after kidney transplantation.

79 e fibrosis is the primary cause of long-term graft failure after organ transplantation.

80 ry DMEK, there was a relatively high rate of graft failure after re-DMEK.

81 = .03), without difference in death-censored graft failure (aHR (0.60) 0.91(1.36) , P = .33) or morta

82 eveloped hypertension had no higher risk for graft failure (aHR 1.03, 95% CI 0.85-1.25, p=0.72).

83 2.63, P < 0.001), 1.6-fold increase in liver graft failure (aHR 1.62, P < 0.001), and 1.6-fold increa

84 We found no significant difference in graft failure (aHR = 1.27; P = .12) and mortality (aHR =

85 tely 2-fold increased risk of death-censored graft failure (aHR, 2.29; 95% CL, 1.59-3.32), all-cause

86 aHR]: 0.861.623.06, P = 0.1), death-censored graft failure (aHR: 0.521.001.91, P > 0.9), DGF (adjuste

87 [aHR]: 0.861.623.06, p=0.1), death-censored graft failure (aHR: 0.521.001.91, p>0.9), DGF (adjusted

88 n (aOR=(1.09)1.16(1.23)), slightly increased graft failure (aHR=(1.01)1.06(1.12)), but decreased mort

89 as no significant difference in the risks of graft failure (aHR=0.861.001.17), death (aHR=0.850.951.0

90 1.02 to 1.23), a more pronounced increase in graft failure (aHR=1.16; 95% CI, 1.08 to 1.26), and no i

91 , 95% CI: 0.98-1.04, P = .4), death-censored graft failure ( [aHR]: 1.02, 95% CI, 0.98-1.06, P = .4),

92 However, graft failure-albeit with full host haemopoietic recover

93 Three re-DMEK eyes developed graft failure, all achieving final BCVA <=0.30 logMAR (S

94 ive was to investigate whether the hazard of graft failure also increases during this age period in F

95 Despite increased risk of graft failure amongst certain ODAT grafts, 5-year surviv

96 Furthermore, rejection leading to graft failure and death had a rare occurrence (1.7% of l

97 ng total population in each US state and (2) graft failure and death post-LT.

98 sociated with increased risks of longer-term graft failure and death, particularly death from cardiov

99 multivariable Cox models for death-censored graft failure and examined whether predictive accuracy (

100 D donor grafts does not increase the risk of graft failure and may help to address waitlist demands.

101 after allo-HCT in CGD, with low incidence of graft failure and mortality in all ages.

102 multivariate regression and between DGF and graft failure and mortality using Cox proportional hazar

103 -censored survival analysis, as well as with graft failure and mortality using Cox regression, adjust

104 h postoperative risks of disease recurrence, graft failure and other complications that may result in

105 nties showing a 13% increased hazard of both graft failure and patient mortality compared to best ter

106 imated glomerular filtration rate decline or graft failure and performed only slightly better than th

107 the only curative option, but a high risk of graft failure and poor immune reconstitution have been o

108 ch indication to determine factors affecting graft failure and rejection at 5 years.

109 rocoagulant phenotype) could predict midterm graft failure and to investigate potential functional ro

110 s 6.3 years, during which 287 death-censored graft failures and 424 deaths occurred.

111 lloimmune causes accounted for only 17.5% of graft failures and only 7.4% of overall graft losses, al

112 VN was associated with an increased risk for graft failure (and functional decline in class 2 at 24 m

113 Twenty-three patients experienced graft failure, and 70 patients (7%) died, with the most

114 IL2RA) with KT outcomes (rejection, graft failure, and death) and hepatic complications (liv

115 (versus IL2RA) with KT outcomes (rejection, graft failure, and death) and hepatic complications (liv

116 e of biliary strictures as a risk factor for graft failure, and does not validate other risk factors

117 modifiable factors, to decrease the risk of graft failure, and improve longer-term outcomes.COMMIT w

118 atological malignancies, serious infections, graft failure, and mortality between KT patients with MG

119 the association of ESW with acute rejection, graft failure, and mortality using multivariable logisti

120 Correlation between chimerism and rejection, graft failure, and patient survival requires further stu

121 Graft and patient survivals, reason for graft failure, and rejection episodes were evaluated in

122 istant herpes simplex virus viremia, primary graft failure, and sinusoidal obstruction syndrome.

123 Death was common in the first year after graft failure, and the cause was most commonly cardiovas

124 transplantation, the factors associated with graft failure, and the immunological basis of corneal al

125 des better insight in the eventual causes of graft failure, and their relative contribution, highligh

126 ty fungal infections, potential increases in graft failures, and antifungal costs.

127 splants, the rates of acute rejection and/or graft failure are comparable to or greater than those of

128 Three hundred forty-one patients had first graft failure as a result of BKVAN, whereas 13 260 had f

129 a result of BKVAN, whereas 13 260 had first graft failure as a result of other causes.

130 Graft failure at 1 year is greater for donors with AKI t

131 ociated with a higher risk of early pancreas graft failure at 3 months.

132 However, the risk of graft failure at 5 years was similar for recipients of a

133 The rate of graft failure at final follow-up was significantly highe

134 ney features as predictors of death-censored graft failure at three transplant centers participating

135 Rates of graft failure attributable to rejection (36.7% vs. 5.9%,

136 Two patients experienced secondary graft failure attributable to viral infections.

137 year estimated glomerular filtration rate or graft failure between groups 1 and 2 (41.5 +/- 18 vs 41.

138 A similar trend was seen in death-censored graft failure between the groups.

139 Transplant rejection increased the risk of graft failure both overall (P = .017; OR = 3.9; 95% CI 1

140 is was a composite endpoint of treated AR or graft failure by 1-year posttransplantation.

141 14 (3%) died, and 23 (4%) had death-censored graft failure by 12 months.

142 Graft failure by 6 months was more than 3 times higher f

143 NRP appears to decrease graft failure by restoring oxygenated blood as the first

144 s of graft duration and risk of dying before graft failure, cancer, cardiovascular disease, diabetes,

145 visual acuity, and a lower rate of secondary graft failure compared to DSEK during the first postoper

146 humor of patients undergoing repeat DMEK for graft failure, compared to primary DMEK.

147 Reasons for intrinsic graft failure comprised rejection, acute tubular necrosi

148 Cumulative incidences of graft failure, cytomegalovirus, and/or adenoviral infect

149 otherwise lost their grafts (death-censored graft failure [DC-GF], N = 295, 8.2%) or maintained func

150 the effect between ethnicity, death-censored graft failure (DCGF) and death with a functioning graft

151 those who did not, and 5-year death-censored graft failure (DCGF) was 20.6% vs 10.1% (P < .001).

152 the effect between ethnicity, death-censored graft failure (DCGF), and death with a functioning graft

153 Secondary outcomes included death-censored graft failure, death with a functioning graft, all-cause

154 with a functioning graft and 154 (42.2%) to graft failure defined as return to dialysis or retranspl

155 An increased rate of graft failure due to hepatic artery thrombosis <=14 days

156 However, graft failure due to stenosis reduces the long-term bene

157 transplant associated with increased risk of graft failure during follow-up.

158 m the Cox model indicated that the hazard of graft failure during the age period 13 to 23 years was a

159 ssociated with older age at transplant, ever graft failure, earlier era of transplant, preexisting ce

160 ssociated with older age at transplant, ever graft failure, earlier era of transplant, preexisting ce

161 n both groups, as was the incidence of early graft failure (EGF).

162 al acuity improvement, primary and secondary graft failure, endothelial rejection, intraocular pressu

163 idney donor transplant, and 40 (22.1%) had a graft failure event.

164 For graft failure excluding death with a functioning graft,

165 y for kidney transplantation, variability in graft failure exists.

166 and GD significantly increased the risk for graft failure following DSAEK.

167 a large difference in the risk of all-cause graft failure for recipients of a standard criteria dece

168 16, we estimated the cumulative incidence of graft failure for recipients of DCD grafts, comparing th

169 d liver-type fatty acid binding protein with graft failure (GF) and death-censored GF (dcGF) using Co

170 dent and incremental risk factors for kidney graft failure (GF) beyond those MMs assessed at the anti

171 Graft failure (GF) occurred in 26 patients (16%), severe

172 tween immunohaematological complications and graft failure, graft rejection, or death.

173 n the numbers of patients with postoperative graft failure, graft rejection, or subsequent surgery at

174 s with chronic injury as presumed reason for graft failure had prior rejection episodes, potentially

175 ated with an 8% decline in the rate of total graft failure (hazard ratio [HR], 0.92; 95% confidence i

176 e interval [95% CI], 1.199-3.863) and 1 year graft failure (hazard ratio, 1.386; 95% CI, 1.037-1.853)

177 pact graft survival, with 43% higher risk of graft failure, highlights the tradeoff between transplan

178 Those with impaired graft function had more graft failures; however, this result was not statistical

179 d that donor male gender was associated with graft failure (HR = 2.87; P = 0.04) and mortality (hazar

180 High center volume was protective for graft failure (HR, 0.70; P = 0.037) compared with low ce

181 9), death (HR, 1.20; 95% CI, 1.07-1.34), and graft failure (HR, 1.17; 95% CI, 1.05-1.30) when compare

182 ies were associated with 33% higher rates of graft failure (HR, 1.33; 95% CI, 1.03-1.72).

183 ce interval [CI], 1.14-2.45; P = 0.0085) and graft failure (HR, 1.68; 95% CI, 1.35-2.1; P <0.0001) on

184 Baseline hazard ratios (HRs) for graft failure (HR, 4.69; P = 0.009) and death (HR, 7.60;

185 ssess the relationship between SES and total graft failure (ie, return to chronic dialysis, preemptiv

186 h topical steroids in 2 eyes (9%), secondary graft failure in 2 eyes (9%), and cataract in 1 of 3 pha

187 uary 11, 2019 to address the problem of high graft failure in adolescent and young adult (AYA) solid

188 has been identified, the eventual causes of graft failure in individual cases remain ill studied.

189 HOUSES) would serve as a predictive tool for graft failure in patients (n = 181) who received a kidne

190 (95%CI,6.0-63.9;p<0.0001) increased risk of graft failure in patients positive for both DSA and anti

191 CI, 6.0-63.9; P < 0.0001) increased risk of graft failure in patients positive for both DSA and anti

192 main long-term complications leading to late graft failure in penetrating keratoplasty (PK).

193 t there has been residual concern about late graft failure in the absence of maintenance prednisone.

194 althy donors modestly predict death-censored graft failure in the recipient, independent of donor or

195 n did not portend a higher risk of recipient graft failure in the same way as eventual post-donation

196 n did not portend a higher risk of recipient graft failure in the same way as eventual postdonation E

197 transplant was not associated with death or graft failure in the year after transplant, but was asso

198 hould be cognizant of the high likelihood of graft failure in this setting.

199 lower likelihood of retransplantation after graft failure in those aged 18 to 24 years.

200 The risk of graft failure in young kidney transplant recipients has

201 2 (3%), 2 (8%), and 54 (46%) death-censored graft failures in the control, subclinical, and clinical

202 There were 36% uncensored graft failures in the dnDSA+ group and 17% uncensored fa

203 raft failures in the DSA- group and 59 (38%) graft failures in the DSA+ group, which was not statisti

204 There were 12 (48%) graft failures in the DSA- group and 59 (38%) graft fail

205 histocompatibility antigen, associated with graft failure, in univariate and multivariate models (ha

206 histocompatibility antigen, associated with graft failure, in univariate and multivariate models (HR

207 The leading cause of synthetic graft failure includes thrombotic occlusion and intimal

208 ior to liver transplantation, as the risk of graft failure increases with the level of infiltrated fa

209 Factors that predicted death-censored graft failure independent of both donor and recipient cl

210 SCT outcomes including primary and secondary graft failure, lethal GvHD, and stable, disease-free ful

211 mismatch load and de novo DSA occurrence and graft failure, mainly explained by DQ antibody-verified

212 ocating and retrieving cells in the event of graft failure may pose a surgical challenge.

213 nge, 0%-22%) after DMEK, followed by primary graft failure (mean, 1.7%; range, 0%-12.5%), secondary g

214 ure (mean, 1.7%; range, 0%-12.5%), secondary graft failure (mean, 2.2%; range, 0%-6.3%), and immune r

215 tion (mean, 10%; range, 0%-45%), and primary graft failure (mean, 5%; range, 0%-29%).

216 re found to be protective for death-censored graft failure; multiple transplants, dnDSA, requirement

217 full-thickness graft failure (n = 8), DSAEK graft failure (n = 3), and pseudophakic bullous keratopa

218 Indications for DSAEK were full-thickness graft failure (n = 8), DSAEK graft failure (n = 3), and

219 Primary and secondary graft failure occurred in 3 (0.3%) and 2 eyes (0.2%), re

220 es developed allograft rejection, no primary graft failures occurred, and 6% of the eyes developed se

221 uced successful detection rates of excessive graft failures of 15%, 62%, and 73% and false alarm rate

222 candidates have suggested increased risk of graft failure or death.

223 rvival, and transplant survival (earliest of graft failure or patient death) for deceased-donor kidne

224 The ability to predict graft failure or primary nonfunction at liver transplant

225 >female [F]) corneas were at greater risk of graft failure or rejection.

226 rejection (odds ratio [OR], 0.87; P = 0.63), graft failure (OR, 0.45; P = 0.08), or death (OR, 0.34;

227 the probability of corneal transplantation, graft failure, or both were calculated based on data fro

228 d in our hospital with no 6-month rejection, graft failure, or death in the recipients.

229 1, 2000, and December 31, 2017, without AR, graft failure, or mortality during KT admission, and com

230 were associated with significantly increased graft failure (P = .012).

231 rushes (p = .002) and improved prediction of graft failure (p = .02).

232 No associations were observed for graft failure (P = 0.18).Vitamin B-6 deficiency is commo

233 nteraction was statistically significant for graft failure (P=0.04) and mortality (P=0.003), but not

234 f graft success (unadjusted hazard ratio for graft failure per additional day of PT, 1.10; 95% CI, 1.

235 ac allograft vasculopathy (CAV), and primary graft failure (PGF).

236 ical covariates (including weights for death/graft-failure), principal components and combined donor-

237 The total all-cause graft failure rate at 5 years was 0.58% for DALK (2 of 3

238 nsplant-related mortality was 21.7%, and the graft failure rate was 6.7%.

239 ter penetrating keratoplasty leads to a high graft failure rate.

240 sented during long-term follow-up with a low graft failure rate: 5% class 1, vs 30% class 2, vs 50% c

241 igher HOUSES (Q2-Q4) had significantly lower graft failure rates (adjusted hazard ratio, 0.47; 95% co

242 Primary graft failure rates and rebubling rates were similar.

243 he CEA was sensitive to potential changes in graft failure rates, underlining the importance of long-

244 tecting higher than expected (ie, excessive) graft failure rates.

245 unologic rejection, herpetic recurrence, and graft failure rates.

246 ctive, patients with higher HOUSES had lower graft failure rates.

247 ions, and did not have any increased risk of graft failure, rejection, or subsequent surgery at posto

248 jection (13.3% vs 10.5%, P = 0.36) and liver graft failure requiring re-transplantation (3.2% vs 2.3%

249 One graft failure resulted from surgeon error in interpretin

250 ath (adjusted hazard ratio [aHR] = 11.79) or graft failure/retransplantation (aHR = 3.24).

251 ble mixed Cox proportional hazards model for graft failure revealed that donor aged 3-10 years had a

252 ceased kidney donors which reflects relative graft failure risk associated with deceased donor charac

253 association between recipient sex and kidney graft failure risk differs by recipient age and donor se

254 s aged >/=45 years had a significantly lower graft failure risk than their male counterparts had (0.9

255 aged 15-24 years had a significantly higher graft failure risk than their male counterparts had (1.2

256 Overall graft failure risk was higher among HLA-mismatched versu

257 ree survival, defined as being alive without graft failure; risk factors were studied using a Cox reg

258 edication adherence may contribute to higher graft failure risks observed in girls and young women co

259 females of all ages had significantly higher graft failure risks than males (adjusted hazard ratios 0

260 thelial cell count (ECC), rates of secondary graft failure (SGF), and postoperative complications.

261 dents) was associated with a similar risk of graft failure (subdistribution hazard ratio [sHR] 0.74;

262 -stage renal disease (ESRD) also have higher graft failure, suggesting the 2 donor kidneys share risk

263 o subsequently develop ESRD also have higher graft failure, suggesting the two donor kidneys share ri

264 ad a slightly higher risk for posttransplant graft failure than patients traveling <=60 miles (hazard

265 survival among the specific causes for first graft failure, the BK group had better graft survival th

266 n systolic blood pressure is associated with graft failure, the reported diagnosis of hypertension as

267 n systolic blood pressure is associated with graft failure, the reported diagnosis of hypertension as

268 haemoglobinopathies is possible, and primary graft failure-the main problem previously reported-might

269 OP that was associated with a higher risk of graft failure through 3 years (hazard ratio: 3.42 [1.01,

270 s (N = 655) were monitored for early or late graft failure through 3 years.

271 lyomavirus (BKPyV) replication causes kidney graft failure through BKPyV-associated nephropathy (BKPy

272 (quartiles: Q1 [lowest] to Q4 [highest]) and graft failure until last follow-up date (December 31, 20

273 An index that is derived to predict graft failure using donor and recipient factors, based o

274 rly post-donation hypertension and recipient graft failure using propensity score-weighted Cox propor

275 arly postdonation hypertension and recipient graft failure using propensity score-weighted Cox propor

276 e effect in patients with DSA on the risk of graft failure via AMRh.

277 The incidence of secondary graft failure was 0.16 and 0.17 (P = .85), respectively.

278 unologic rejection, herpetic recurrence, and graft failure was 9.7%, 7.8%, and 7.6%, respectively.

279 Graft failure was associated with a significantly slower

280 However, graft failure was associated with post-donation systolic

281 However, graft failure was associated with postdonation systolic

282 Acute graft failure was defined as AKI stages 1 to 3 (Acute Ki

283 The hazard of graft failure was estimated at each current age using a

284 The risk of graft failure was found to increase around the age of 13

285 Secondary graft failure was lower in the DMEK group (DMEK 0% vs. D

286 Graft failure was lower with HMPO(2) (three [3%] of 106)

287 nts of a living donor, the rate of all-cause graft failure was not statistically higher for recipient

288 e importance of sac growth as a predictor of graft failure was overlooked.

289 al differentiation of prerenal and intrinsic graft failure was performed either by biopsy or by a cli

290 Graft failure was the predominant cause of mortality.

291 factors that increased a risk of patient or graft failure were a poor performance status (hazard rat

292 ications, graft survival rate, and causes of graft failure were analyzed.

293 The main causes of graft failure were distinct for early failures, where st

294 med DSA demonstrated elevated risks of early graft failure, whereas those with de novo DSA experience

295 irradiation to 400 cGy substantially reduced graft failure while maintaining the safety of haploident

296 0.03) were associated with increased risk of graft failure, while estimated glomerular filtration rat

297 e also determined the death-censored risk of graft failure with each structural feature after adjusti

298 One (6%) of 17 patients had primary graft failure with recovery of host haemopoiesis.

299 luate management of patients with intestinal graft failure with special reference to indications and

300 ransplant factors influencing the outcome of graft failure within 30 days were selected using a machi